Diabetes Drug Deal: Zydus & Lupin Unite for Wider Reach

Zydus Lifesciences and Lupin Limited have entered into a significant licensing and supply agreement aimed at increasing patient access to the diabetes medication, Semaglutide Injection. This collaboration focuses on making the 15 mg/3 ml dose, delivered via a user-friendly reusable pen, more widely available across India.

Under the terms of the deal, Lupin will benefit from initial licensing fees and milestone payments. The partnership strategically enhances patient reach for cutting-edge diabetes care and chronic weight management solutions. Lupin will have semi-exclusive rights to co-market Semaglutide in India, leveraging Zydus's innovative product.

Lupin’s Managing Director, Nilesh Gupta, stated that this alliance strengthens their commitment to advanced cardio-metabolic disease treatments. He highlighted that as GLP-1 therapies evolve globally, this collaboration fortifies Lupin's diabetes portfolio and addresses unmet patient needs. Both companies aim to expand access to high-quality treatments and support healthcare professionals throughout India.

Semaglutide is indicated for adults with poorly managed Type 2 diabetes, as an adjunct to diet and exercise. It is also approved for long-term weight management in adults, complementing increased physical activity and a calorie-restricted diet. Zydus had previously licensed similar products, including Desidustat for anemia in CKD patients, to other entities.